Nutra Pharma Corp NPHC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NPHC is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $759,685.22
- Volume/Avg
- 1,181 / 620,540
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nutra Pharma Corp operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. It also develops proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Some of its drug names are Cobroxin, Nyloxin, RPI-78M, RPI-MN and Pet Pain-Away.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 4
- Website
- https://www.nutrapharma.com
Valuation
|
Metric
|
NPHC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
NPHC
Financial Strength
|
Metric
|
NPHC
|
|---|---|
Quick Ratio | 0.02 |
Current Ratio | 0.03 |
Interest Coverage | 10.77 |
Quick Ratio
NPHC
Profitability
|
Metric
|
NPHC
|
|---|---|
Return on Assets (Normalized) | 964.38% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NPHC
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Knvbcwfgb | Tzkw | $70.0 Bil | |
MKKGY
| Merck KGaA ADR | Pkmypmkxj | Xfqpws | $68.4 Bil | |
HLN
| Haleon PLC ADR | Tnqpqds | Bmq | $37.0 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Blwrqrwx | Sxjz | $14.5 Bil | |
VTRS
| Viatris Inc | Xmcdxkvy | Bcy | $13.4 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Drdcbbwn | Gvh | $12.0 Bil | |
CTLT
| Catalent Inc | Wwkvsftt | Cxsky | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Zdtjdhkh | Hyvdk | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Vrfcznmf | Hldk | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Tyfhhcxqx | Tcgtnvp | $3.5 Bil |